Drug intelligence / Profile preview

deudextromethorphan + quinidine

Development stage
Unknown
Lead developer
Otsuka Holdings
Modality
Small Molecules
Administration
Oral
01

Overview

**deudextromethorphan + quinidine** is a fixed-dose combination drug that contains deudextromethorphan (a deuterated form of dextromethorphan) and quinidine. It is used primarily in the treatment of pseudobulbar affect (PBA), which presents as sudden, uncontrollable episodes of laughing or crying seen in neurological conditions like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)[1][2][5]. Deudextromethorphan acts as a sigma-1 receptor agonist, a serotonin–norepinephrine reuptake inhibitor, and an NMDA receptor antagonist. Quinidine is included at a low dose to inhibit CYP2D6, thereby increasing plasma concentrations of deudextromethorphan[2][3][5]. The precise mechanism by which this combination benefits PBA is unknown, but these combined actions are thought to modulate emotional expression and neurotransmitter function in the CNS[3][5].

Brand names
Nuedexta
Other names
deudextromethorphan and quinidine
02

Targets

SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)Nicotinic Acetylcholine ReceptorNMDAR (Glutamate receptor ionotropic, NMDA)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on deudextromethorphan + quinidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on deudextromethorphan + quinidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call